This session at ACR Convergence 2022, on Monday, Nov. 14, 2022, from 9–10 a.m. EST, will examine guidelines and current evidence regarding the management and outcomes of patients with ankylosing spondylitis (AS). Alexis Ogdie, MD, a rheumatologist and associate professor of Medicine at the University of Pennsylvania, Philadelphia, will present data to highlight the evolution…
Top Research in Gout Presented at ACR Convergence 2022
With ~60 research abstracts on gout accepted for presentation at ACR Convergence 2022, filtering the noise to get to the key thoughts may be challenging. Lisa Stamp, MBChB, PhD, can help. A rheumatologist, professor of medicine and the associate dean of research at the University of Otago in Christchurch, New Zealand, she has extensively researched…
Gout Is an Autoinflammatory Metabolic Disease
On Monday, Nov. 14, Michael Pillinger, MD, will moderate the session Gout Is an Autoinflammatory Metabolic Disease at ACR Convergence 2022. This session will address the autoinflammatory nature of gout and highlight it as an IL-1β-mediated diseases. Increasing knowledge on the inflammatory mechanisms of gout has implications for disease management. These engaging talks will review…
Support Your Practice & Expand the Impact of Your Expertise Through Advocacy
ACR Convergence 2022 will offer several opportunities to learn to leverage your expertise to support the rheumatology community, keep practices solvent and improve care of patients with rheumatic diseases. Look for sessions that explore why and how to pursue effective rheumatology advocacy and how to turn challenges into actionable results.
How to Help Patients with Chronic Pain
Pain is more than nociception, and pain management is more than medication. Delia Chiaramonte, MD, provided insights into how rheumatologists can help their patients ease and manage chronic pain.
Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising
In a small preliminary study, the novel MK2 inhibitor, CC-99677, was safe and well tolerated by healthy participants. With daily dosing, the agent sustained reductions of tumor necrosis factor alpha and other cytokines for 14 days.
Medication Preferences & Current Practices for PsA
With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.
Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…
Pre-Eclampsia Risk & Rheumatic Disease
Secher et al. evaluated the risk of pre-eclampsia in pregnant patients with RA, axSpA or PsA, assessing the effect of disease activity and disease-modifying anti-rheumatic drugs on this risk.
Improving Bone Mineral Density: Risedronate vs. Denosumab
Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate.
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 37
- Next Page »